Special articleTreatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal☆
References (76)
- et al.
Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection
- et al.
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
Lancet
(1989) - et al.
Hepatitis B virus unable to secrete e antigen
Gastroenterology
(1991) - et al.
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B
J Hepatol
(1990) - et al.
Antiviral therapy of hepatitis C—present and future
J Hepatol
(1993) - et al.
Recombinant leucocyte interferon treatment of chronic hepatitis B
- et al.
Mortality of hepatitis B positive blood donors in England and Wales
Lancet
(1985) - et al.
Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV)
J Hepatol
(1990) - et al.
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
Gastroenterology
(1992) - et al.
Spontaneous bacterial peritonitis in patients with hepatitis B-related cirrhosis and hepatocellular carcinoma
Gastroenterology
(1991)
Passive immunoprophylaxis after liver transplantation in HBsAg-posititive patients
Lancet
Commodity, the bias of the world
The Science of the Total Environment
Trying to value a life
Journal of Public Economics
Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
Lancet
Design of future cost benefit studies
Am Heart J
Hepatitis C virus
Chronic viral hepatitis
The natural history of community-acquired hepatitis C in the United States
N Engl J Med
A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children
Hepatology
Changes of serum HBV-DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis
Liver
Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers
Clin Infect Dis
Intrahepatic expression of HBcAg in chronic HBV hepatitis: lessons from molecular biology
Hepatology
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections
Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity
J Gen Virol
Hepatitis B virus (HBV)-specific cytotoxic Tcell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines
J Virol
Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection
J Infect Dis
Concurrent hepatitis C virus and hepatitis delta virus superinfection in patients with chronic hepatitis B virus infection
J Med Virol
Hepatitis delta virus disease
Prog Liver Dis
Presence and significance of hepatitis B virus replication in chronic type D hepatitis
Prog Clin Biol Res
Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: a birth order study
Am J Epidemiol
The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease
Hepatology
Hepatitis B virus
Serological markers of hepatitis B virus and alphafetoprotein levels preceding primary hepatocellular carcinoma in Alaskan Eskimos
Lancet
Increasing incidence of hepatocellularcarcinoma possibly associated with non-A, non-B hepatitis in Japan, disclosed by hepatitis B virus DNA analysis of surgically resected cases
Cancer Res
Relative risk of hepatocellular carcinoma in HBsAg positive vs alcoholic cirrhosis
Hepatitis B-related sequelae
Identification of integrated hepatitis B virus DNA sequences in human hepatocellular carcinomas
Hepatology
Detection of hepatitis C virus cDNA sequence by the polymerase chain reaction in hepatocellular carcinoma tissues
Jpn J Med Sci Biol
Cited by (145)
Drugs induced pulmonary arterial hypertension
2013, Presse MedicaleCitation Excerpt :In conclusion, large inhibition spectrum and lack of specificity of TKIs may be responsible for unexpected toxicities, even at the pulmonary vascular level. The interferons (IFNs) comprise an evolutionary conserved family of secreted proteins that participate as extracellular messengers in a wide variety of responses, including antiviral, antiproliferative and immunomodulatory and developmental activities that act to maintain homeostasis and in-host defence [42,43]. IFNs are classified as helical cytokines and are categorized as type I or type II, according to their physical and functional characteristics.
Economics of chronic hepatitis B and hepatitis C
2007, Journal of HepatologyCitation Excerpt :Thus, considering only drug costs does not recognize the clinical benefit of treatment, so while a stricter stopping rule reduces drug costs, it does not incorporate the missed opportunity to eradicate hepatitis C infection. Table 4[38,39,48–53] summarizes published cost-effectiveness analyses in incremental cost per life-year gained and cost-utility analyses in incremental cost per QALY gained. Organized by comparator, the table starts first with the earliest effective therapies compared with placebo.
Drug induced pulmonary arterial hypertension
2018, Interni Medicina pro PraxiA mini-review of anti-hepatitis B virus activity of medicinal plants
2017, Biotechnology and Biotechnological Equipment
- ☆
The following investigators formed the advisory board: J.-P. Benhamou (France), V. Feinman (Canada), C. Niederau (Germany), M. Rizzetto (Italy), J. Rodés (Spain), J. Garcia de Ancos (United Kingdom), and S. Schalm (The Netherlands).